Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer (Q38011768)

27 August 2017

Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer (English)

1 reference

27 August 2017

1 reference

1 reference

1 reference

ChEBI release 2020-05-28

5

Fortunato Ciardiello

1 reference

27 August 2017

Teresa Troiani

1

1 reference

27 August 2017

Erika Martinelli

2

1 reference

27 August 2017

Michele Orditura

3

1 reference

27 August 2017

Ferdinando De Vita

4

1 reference

27 August 2017

Floriana Morgillo

6

1 reference

27 August 2017

language of work or name

English

0 references

publication date

22 May 2012

1 reference

Expert Opinion on Investigational Drugs

27 August 2017

1 reference

27 August 2017

21

1 reference

27 August 2017

7

1 reference

27 August 2017

949-959

1 reference

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Anti-angiogenic treatment of gastrointestinal malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

VEGF-D promotes the metastatic spread of tumor cells via the lymphatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Ramucirumab (IMC-1121B): a novel attack on angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Anti-angiogenic therapy: rationale, challenges and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast gro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.689287

10.1517/13543784.2012.689287

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference